Overcoming ABCG2-mediated drug resistance using tyrosine kinase inhibitors may thus ultimately benefit the anti-cancer efficacy of transcriptional CDK inhibitors and other ABCG2 substrates in the clinic. The gene discussed is ABCG2; the disease is cancer.